Diabetes Management Delivery and Pregnancy Outcomes in Women with Gestational Diabetes Mellitus during the First Wave of the 2020 COVID-19 Pandemic: A Single-Reference Center Report
Table 2
Diabetes medical care and glycemic control according to the study group.
Variable
Patients treated during COVID-19 pandemic , (%)
Control group , (%)
value
Telemedicine use ( (%))
36 (49.3)
0
<0.01
GDM treatment ( (%))
(i) Diabetic diet only
36 (49.3)
29 (35.3)
0.08
(ii) Basal insulin
25 (34.2)
32 (39.0)
0.54
(iii) MDI
12 (16.4)
19 (23.2)
0.30
(iv) Basal plus
1 (1.4)
2 (2.4)
0.50
Total daily insulin dose (IU)
0.57
Frequency of SMBG per day (( (%))
(i) 0–2
0
1 (1.2)
0.34
(ii) 3–5
16 (21.9)
11 (13.4)
0.16
(iii) 6–10
57 (78.1)
67 (81.7)
0.57
(iv) 11 and more
0
3 (3.6)
0.28
Fasting blood glucose levels (mg/dl)
0.70
Postprandial glycemia (60 minutes after a meal) (mg/dl)
0.70
Difficulties in GDM treatment (n (%))
(i) Not reported
8 (11.0)
1 (1.2)
0.01
(ii) Diet
36 (49.3)
29 (35.4)
0.08
(iii) Technique of insulin administration
16 (21.9)
19 (23.2)
0.85
(iv) Insulin dosing
5 (6.8)
1 (1.2)
0.07
(v) Glycaemia self-monitoring
20 (27.4)
7 (8.5)
<0.01
(vi) Fear of hyperglycemia
23 (31.5)
22 (26.8)
0.52
(vii) Fear of hypoglycemia
3 (4.1)
2 (2.4)
0.56
Recording and presentation of glycemic data ( (%))
